FDA Approves Tyruko for Multiple Sclerosis and Crohn’s Disease Treatment

Medication offers options to those who have relapsing forms of the disease. The U.S. Food and Drug Administration (FDA) has authorized Tyruko (natalizumab-sztn), the first biosimilar to Tysabri…

Read More

Back to top
FE3